Selective Ion Channel Antagonists for CNS Neurological Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological and neurodevelopmental diseases associated with aberrant expression of ion channels in CNS neuronal cells, such as Pitt-Hopkins Syndrome, schizophrenia, and autism, face challenges in specificity and efficacy due to nonspecific effects on ion channels, leading to off-target adverse effects.
Innovation Solution
Administration of specific therapeutic antagonists targeting SCN10a and KCNQ1 ion channels to block or suppress their aberrant expression and activity in CNS neuronal cells, using compounds like A-803467, PF-04531083, and UCL2077, which are designed to cross the blood-brain barrier and minimize PNS delivery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If nonspecific ion channel antagonists are used to treat neurological disorders, then broad ion channel blocking is achieved, but off-target adverse effects increase
Solution Approach 1:
The patent segments the ion channel targeting approach by developing antagonists with specific selectivity for particular ion channel subtypes (e.g., Nav1.6, Nav1.7, KCNQ1) rather than using broad-spectrum blockers. This segmentation allows therapeutic action on specific pathological channels while sparing other channels, thereby reducing off-target adverse effects while maintaining effective treatment.
Solution Approach 2:
The patent applies local quality by designing antagonists that exhibit different selectivity profiles for ion channels in different tissue compartments. The compounds demonstrate preferential binding to CNS neuronal ion channels over peripheral nervous system channels, achieving location-specific therapeutic action that maximizes efficacy while minimizing systemic side effects.
2Object-affected harmful factors
If selective ion channel antagonists are used to reduce off-target effects, then specificity is improved, but the ability to treat diverse neurological conditions is reduced
Solution Approach 1:
The patent achieves universality by developing a series of selective ion channel antagonists that can be matched to different neurological disorders based on their specific pathophysiology. The same selective antagonist mechanisms can treat diverse conditions (epilepsy, pain, schizophrenia, autism) by targeting the appropriate ion channel subtype involved in each disorder, providing a versatile therapeutic platform.
Solution Approach 2:
The patent employs dynamics by allowing flexible selection and combination of different selective antagonists based on the specific neurological condition being treated. The therapeutic approach is not fixed but can be dynamically adjusted to match the patient's specific ion channel abnormalities, enabling effective treatment across diverse disorders while maintaining high specificity.
3Quantity of substance
If ion channel antagonists are administered systemically, then broad tissue exposure is achieved, but CNS delivery is insufficient while PNS exposure increases
Solution Approach 1:
The patent applies local quality by designing antagonists with differential distribution patterns that achieve higher concentrations in the CNS relative to peripheral tissues. The compounds exhibit preferential accumulation in brain tissue through mechanisms such as blood-brain barrier penetration or active transport, creating a therapeutic gradient that maximizes CNS efficacy while minimizing PNS exposure.
Solution Approach 2:
The patent employs transport mechanisms as intermediaries to facilitate selective CNS delivery of the antagonists. These may include exploitation of endogenous transport systems at the blood-brain barrier or use of carrier molecules that preferentially deliver the therapeutic agents to CNS tissues, thereby acting as mediators that enhance CNS penetration while limiting peripheral distribution.
Data Source
AI summary
Provided are methods for treating and/or reducing the symptoms of a neurological or neurodevelopmental disease or disorder characterized by ectopic expression of certain ion channels, in particular, the Nav1.8 subtype SCN10a sodium channel, or the KCNQ1 potassium channel, in neuronal cells of the central nervous system (CNS) of a subject by administering to a subject in need an antagonist of one or both of these ion channels, and in particular, an antagonist of SCN10a, to block, reduce, or suppress the aberrant CNS neuronal ion channel expression and/or activity and normalize behavioral and cognitive defects associated with the neurological and neurodevelopmental disease or disorder, so as to treat and/or reduce the symptoms of the neurological or neurodevelopmental disease or disorder. Examples of such diseases or disorders that may be treated by the described methods include, for example, Pitt-Hopkins Syndrome (PTHS), autism, autism spectrum disorder, schizophrenia, 18q syndrome and the like.